Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1300 of 3499 entries
View as:

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01727089 Org: User:
Start: 11/01/12 End: 08/08/17 Due: 08/08/18

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00080847 Org: User:
Start: 03/31/04 End: - Due: -

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT01105390 Org: User:
Start: 04/30/10 End: - Due: -

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00977574 Org: User:
Start: 09/14/09 End: 03/06/26 Due: 03/06/27

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

Phase: N/A Priority: Normal
NCT ID: NCT03728881 Org: User:
Start: 04/01/19 End: 04/23/24 Due: 04/23/25

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00004029 Org: User:
Start: 12/31/96 End: - Due: -

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06487481 Org: User:
Start: 07/02/25 End: 12/01/40 Due: 12/01/41

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00006364 Org: User:
Start: 11/30/99 End: - Due: -

Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies

Phase: N/A Priority: Normal
NCT ID: NCT00341263 Org: User:
Start: 11/21/03 End: 02/19/20 Due: 02/19/21

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05445882 Org: User:
Start: 04/01/24 End: 04/01/24 Due: 04/01/25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Phase: N/A Priority: Normal
NCT ID: NCT01254578 Org: User:
Start: 11/24/10 End: 11/09/12 Due: 11/09/13

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00445341 Org: User:
Start: 11/27/06 End: 10/18/12 Due: 10/18/13

Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01126502 Org: User:
Start: 05/31/10 End: 06/30/12 Due: 06/30/13

CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00079235 Org: User:
Start: 02/29/04 End: - Due: -

R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005843 Org: User:
Start: 05/31/00 End: - Due: -

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05019716 Org: User:
Start: 07/13/22 End: 12/01/25 Due: 12/01/26

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00637481 Org: User:
Start: 03/31/08 End: 10/31/12 Due: 10/31/13

Pediatric cGVHD Symptom Scale

Phase: N/A Priority: Normal
NCT ID: NCT04044365 Org: User:
Start: 10/02/19 End: 12/31/25 Due: 12/31/26

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03831932 Org: User:
Start: 03/16/20 End: 03/14/26 Due: 03/14/27

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Phase: N/A Priority: Normal
NCT ID: NCT04494113 Org: User:
Start: 02/08/22 End: 06/01/26 Due: 06/01/27

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

Phase: N/A Priority: Normal
NCT ID: NCT06606990 Org: User:
Start: 09/09/25 End: 12/31/26 Due: 12/31/27

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Phase: N/A Priority: Normal
NCT ID: NCT03528642 Org: User:
Start: 05/01/19 End: 12/31/25 Due: 12/31/26

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Phase: N/A Priority: Normal
NCT ID: NCT03212274 Org: User:
Start: 01/30/19 End: 07/31/25 Due: 07/31/26

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Phase: N/A Priority: Normal
NCT ID: NCT00003694 Org: User:
Start: 03/31/99 End: - Due: -

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Phase: N/A Priority: Normal
NCT ID: NCT01143545 Org: User:
Start: 12/07/10 End: 02/26/20 Due: 02/26/21